FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL VS OPEN TRIPLE THERAPY FOR TREATING SEVERE TO VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) FROM A BRAZILIAN PUBLIC HEALTHCARE PERSPECTIVE: A BUDGET IMPACT ANALYSIS

被引：0
|
作者：
Araujo, M. [1 ]
Bernardino, G. [1 ]
Tanaka, S. Y. [1 ]
机构：
[1] GSK, Rio De Janeiro, RJ, Brazil
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE512
引用
收藏
页码：S151 / S151
页数：1
相关论文
共 23 条
  • [1] UMECLIDINIUM/VILANTEROL VERSUS TIOTROPIUM/OLODATEROL IN THE TREATMENT OF SEVERE TO VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE: A BUDGET IMPACT ANALYSIS
    Araujo, M.
    Silva, D.
    Bernardino, G.
    VALUE IN HEALTH, 2023, 26 (06) : S93 - S93
  • [2] Triple Therapy of Fluticasone Furoate, Umeclidinium, Vilanterol- A Compelling Choice in Severe Chronic Obstructive Pulmonary Disease
    Nathan, B. Jagan
    Sahay, Melina, I
    Gautham, A. K.
    Sriram, D. K.
    George, Melvin
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2021, 15 (02) : CP7 - CP7
  • [3] Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system
    Balmaceda, Carlos
    Espinoza, Manuel A.
    Abbott, Tomas
    Peters, Anne
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (05) : 743 - 751
  • [4] Effect of Age on Efficacy and Safety of Multiple Inhaler Triple Therapy with Umeclidinium Added to Fluticasone Furoate/Vilanterol in Chronic Obstructive Pulmonary Disease
    Soule, T.
    Caveney, S.
    Tombs, L.
    Boucot, I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [5] Triple therapy with Fluticasone furoate/Umeclidinium/Vilanterol compared with dual bronchodilation or triple therapy with inhaled corticosteroids/dual bronchodilation in patients with chronic obstructive pulmonary disease
    Harada, Naoko
    Otsuka, Kengo
    Horiuchi, Atsuo
    Shinka, Yoko
    Yamamura, Hiroyuki
    Miyao, Naoki
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [6] Assessment of Peak Inspiratory Flow Rate in Patients with Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship with Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy
    Anderson, M.
    Drummond, M.
    Jain, R.
    Corbridge, T. C.
    Zhu, C.
    Collison, K.
    Hamilton, M.
    Prime, D.
    Martin, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [7] Real-Life Clinical and Functional Effects of Fluticasone Furoate/Umeclidinium/Vilanterol-Combined Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease
    Pelaia, Corrado
    Procopio, Giada
    Deodato, Maria Rosaria
    Florio, Olivia
    Maglio, Angelantonio
    Sciacqua, Angela
    Vatrella, Alessandro
    Pelaia, Girolamo
    RESPIRATION, 2021, 100 (02) : 127 - 134
  • [8] Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annual Moderate and Severe Exacerbations
    Ismaila, A. S.
    Haeussler, K.
    Czira, A.
    Youn, J.
    Malmenas, M.
    Risebrough, N.
    Agarwal, J.
    Nassim, M.
    Sharma, R.
    Compton, C.
    Vogelmeier, C. F.
    Halpin, D. M. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [9] Network Meta-analysis (NMA) of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Compared with other Triple Therapies for the Treatment of chronic obstructive Pulmonary Disease (COPD): A Comparison of annualized Rates of moderate and severe Exacerbations
    Ismaila, A.
    Haeussler, K.
    Czira, A.
    Youn, J.
    Malmenaes, M.
    Risebrough, N.
    Nassim, M.
    Sharma, R.
    Compton, C.
    Vogelmeier, C.
    Halpin, D.
    PNEUMOLOGIE, 2023, 77 : S96 - S96
  • [10] Unveiling the Clinical Profiles for Patients With Asthma and Chronic Obstructive Pulmonary Disease Starting Single-inhaler Triple Therapy With Fluticasone Furoate/Umeclidinium/Vilanterol (FF/ UMEC/VI)
    Narendra, D.
    Baptist, A. P.
    Lee, L.
    Noorduyn, S. G.
    Liu, M.
    Igboekwe, E. E.
    Veeranki, P.
    Kahle-Wrobleski, K.
    Paczkowski, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
123